Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. human disease biology
Show results for
Products
Services

Companies

News
Articles
Videos

Refine by
Date

  • Older

Human Disease Biology Articles & Analysis

8 news found

SeqOne Genomics and the French Thrombotic MicroAngiopathies National reference center (CNR-MAT) pioneer the use of Oxford Nanopore sequencing technology to improve patient outcomes in kidney disease while reducing turnaround times

SeqOne Genomics and the French Thrombotic MicroAngiopathies National reference center (CNR-MAT) pioneer the use of Oxford Nanopore sequencing technology to improve patient outcomes in kidney disease while reducing turnaround times

About SeqOne Genomics SeqOne Genomics offers high-performance genomic analysis solutions for healthcare providers treating patients suffering from cancer, rare and hereditary diseases as well as pharmaceutical companies developing new therapies. ...

BySeqOne S.A.S.


Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference

Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference

High blood glucose can lead to diabetic ketoacidosis and over time, to complications such as kidney disease/failure, eye disease (including vision loss), heart disease, stroke, nerve damage and even death. ...

ByVertex Pharmaceuticals


Suketu Upadhyay Elected to Vertex Board of Directors

Suketu Upadhyay Elected to Vertex Board of Directors

“It’s an honor to join Vertex, a company focused on serial innovation with an industry-leading track record of discovering, developing and commercializing transformative medicines to treat serious diseases. It is particularly exciting to join at such a pivotal time, when the company is in the process of transforming the treatment of multiple serious ...

ByVertex Pharmaceuticals


Vertex Announces Further Expansion in the Boston Seaport at Dedication of the Jeffrey Leiden Center for Cell and Genetic Therapies

Vertex Announces Further Expansion in the Boston Seaport at Dedication of the Jeffrey Leiden Center for Cell and Genetic Therapies

Cell and genetic therapies are two rapidly emerging therapeutic modalities with the potential to treat the underlying cause — and even cure — several of the serious diseases Vertex is working on including sickle cell disease, beta thalassemia, type 1 diabetes and Duchenne muscular dystrophy. ...

ByVertex Pharmaceuticals


Vertex Announces $50 Million Commitment to Health Equity With Three Initial Grants

Vertex Announces $50 Million Commitment to Health Equity With Three Initial Grants

” “I want patients to feel there is somebody in their corner because this disease affects every facet of their lives,” said Sharl Azar, M.D., Medical Director for the Mass General Comprehensive Sickle Cell Disease Treatment Center. ...

ByVertex Pharmaceuticals


Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes

Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes

High blood glucose can lead to diabetic ketoacidosis and over time, to complications such as kidney disease/failure, eye disease (including vision loss), heart disease, stroke, nerve damage and even death. ...

ByVertex Pharmaceuticals


Health Canada Grants Marketing Authorization for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation

Health Canada Grants Marketing Authorization for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation

About Cystic Fibrosis Cystic fibrosis (CF) is a rare, life-shortening genetic disease affecting more than 83,000 people globally. CF is a progressive, multi-organ disease that affects the lungs, liver, pancreas, GI tract, sinuses, sweat glands and reproductive tract. ...

ByVertex Pharmaceuticals


Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease

Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease

If positive, the interim analysis may serve as the basis for Vertex to seek accelerated approval of VX-147 in the U.S. for patients with AMKD. About APOL1-Mediated Kidney Disease APOL1-mediated kidney disease is a form of chronic kidney disease caused by mutations in the APOL1 gene. ...

ByVertex Pharmaceuticals

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical Equipment & Supplies
  • Medical Software
  • Medical Training Courses
  • Medical Industry Services
  • Medical Product Applications

Latest

  • Medical Industry News
  • Medical Industry Events

Publications

  • Medical Industry Articles & Case Studies
  • Medical Industry Books and Publications
  • Medical Industry Journals and Magazines
  • Medical Industry Downloads
  • Medical Industry Videos

Companies

  • Medical Industry Suppliers & Manufacturers

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT